Rosucard, 90 pcs., 10 mg, film-coated tablets
Inside,
without chewing or crushing, swallow whole with water at any time of the day, regardless of food intake.
Before starting therapy with Rosucard®, the patient should begin to follow a standard lipid-lowering diet and continue to follow it during treatment. The dose of the drug should be adjusted individually, depending on the indication and therapeutic response, taking into account current generally accepted recommendations for target lipid levels. If it is necessary to take the drug at a dose of 5 mg, the 10 mg tablet should be divided into 2 parts according to the risk.
The recommended starting dose of Rosucard® for patients starting to take the drug, or for patients transferred from taking other HMG-CoA reductase inhibitors, is 5 or 10 mg 1 time per day.
When choosing the initial dose, one should be guided by the patient’s cholesterol level and take into account the risk of developing cardiovascular complications, and it is also necessary to assess the potential risk of side effects. If necessary, after 4 weeks the dose of the drug can be increased.
Due to the potential for side effects when taking a dose of 40 mg compared to lower doses of the drug (see "Side Effects"), final titration to a maximum dose of 40 mg should only be done in patients with severe hypercholesterolemia and a high risk of cardiovascular complications (especially in patients with hereditary hypercholesterolemia) in whom the target cholesterol level was not achieved when taking a dose of 20 mg and who will be under medical supervision. Particularly careful monitoring of patients receiving the drug at a dose of 40 mg is recommended.
It is not recommended to prescribe a dose of 40 mg to patients who have not previously consulted a doctor. After 2–4 weeks of therapy and/or when the dose of Rosucard® is increased, it is necessary to monitor lipid metabolism parameters (if necessary, dose adjustment is required).
Patients with liver failure.
In patients with liver failure with Child-Pugh scores below 7 points, no dose adjustment of Rosucard® is required. The drug Rosucard® is contraindicated in patients with liver disease in the active phase, a persistent increase in serum activity of liver transaminases (more than 3 times compared to ULN) of unknown origin and patients with liver failure (severity from 7 to 9 points on the Child-Pugh scale ) (see “Contraindications”).
Patients with renal failure.
In patients with mild renal failure, no dose adjustment is required. The recommended initial dose of Rosucard® is 5 mg/day.
In patients with severe renal failure (creatinine clearance <30 ml/min), the use of Rosucard® is contraindicated.
In patients with moderate renal failure (creatinine clearance 30–60 ml/min), the use of Rosucard® at a dose of 40 mg/day is contraindicated (see “Contraindications”).
Elderly patients.
In patients over 65 years of age, no dose adjustment is required.
Special populations
Patients with a predisposition to myopathy.
The use of Rosucard® at a dose of 40 mg/day is contraindicated in patients with a predisposition to myopathy (see “Contraindications”). When prescribing doses of 10 and 20 mg/day, the recommended initial dose of Rosucard® for this group of patients is 5 mg/day.
Ethnic groups.
When studying the pharmacokinetic parameters of rosuvastatin, an increase in the systemic concentration of the drug was noted in representatives of the Mongoloid race (see “Pharmacokinetics”).
This fact should be taken into account when prescribing Rosucard® to patients of the Mongoloid race. When prescribing doses of 10 and 20 mg, the recommended initial dose of Rosucard® for this group of patients is 5 mg/day. The use of the drug Rosucard® at a dose of 40 mg/day in representatives of the Mongoloid race is contraindicated (see “Contraindications”).
When prescribing Rosucard® with gemfibrozil, the dose should not exceed 10 mg/day.
Genetic polymorphism.
Carriers of the SLCO1B1 (OATP1B1) c.521CC and ABCG2 (BCRP) c.421AA genotypes showed an increase in exposure (AUC) to rosuvastatin compared to carriers of the SLC01B1 c.521TT and ABCG2 c.421CC genotypes. For patients carrying genotypes c.521CC or c.421AA, the recommended maximum dose of Rosucard® is 20 mg/day (see “Pharmacokinetics”, “Special instructions” and “Interaction”).
Concomitant therapy.
Rosucard® binds to various transport proteins (in particular, OATP1B1 and BCRP). When simultaneous use of the drug Rosucard® with drugs (such as cyclosporine, some HIV protease inhibitors, including a combination of ritonavir with atazanavir, lopinavir and/or tipranavir) that increase the concentration of rosuvastatin in the blood plasma due to interaction with transport proteins, the risk of developing myopathy may increase (including rhabdomyolysis) (see “Special Instructions” and “Interaction”). In such cases, the possibility of prescribing alternative therapy or temporarily stopping the use of Rosucard® should be assessed. If the use of the above drugs is necessary, you should read the instructions for use of the drugs before prescribing them simultaneously with the drug Rosucard®, assess the benefit-risk ratio of concomitant therapy and consider reducing the dose of the drug Rosucard® (see “Interaction”).
Rozucard®
Effect of the use of other drugs on rosuvastatin
Transport protein inhibitors:
rosuvastatin binds to some transport proteins, in particular OATP1B1 and BCRP. Concomitant use of drugs that are inhibitors of these transport proteins may be accompanied by an increase in the concentration of rosuvastatin in the blood plasma and an increased risk of developing myopathy (see Table 3 and sections “Dosage and Administration” and “Special Instructions”).
Cyclosporine:
with simultaneous use of rosuvastatin and cyclosporine, the AUC of rosuvastatin was on average 7 times higher than the value observed in healthy volunteers (see Table 3). Does not affect plasma concentrations of cyclosporine. Rosucard® is contraindicated in patients taking cyclosporine (see section "Contraindications").
Human immunodeficiency virus (HIV) protease inhibitors:
Although the exact mechanism of interaction is unknown, coadministration of HIV protease inhibitors may result in a significant increase in rosuvastatin exposure (see Table 3). A pharmacokinetic study of the simultaneous use of 20 mg rosuvastatin with a combination drug containing two HIV protease inhibitors (400 mg lopinavir/100 mg ritonavir) in healthy volunteers resulted in an approximately two-fold and five-fold increase in AUC(o_24) and Cmax of rosuvastatin, respectively. Therefore, simultaneous use of the drug Rosucard® and HIV protease inhibitors is not recommended (see sections “Method of administration and dosage”, “Special instructions”, table 3).
Gemfibrozil and other lipid-lowering drugs:
The combined use of rosuvastatin and gemfibrozil leads to a 2-fold increase in the Cmax and AUC of rosuvastatin (see section “Special Instructions”). Based on specific interaction data, a pharmacokinetically significant interaction with fenofibrate is not expected; a pharmacodynamic interaction is possible. Gemfibrozil, fenofibrate, other fibrates and lipid-lowering doses of nicotinic acid (more than 1 g per day) increased the risk of myopathy when used concomitantly with HMG-CoA reductase inhibitors, possibly due to the fact that they can cause myopathy when used in monotherapy (see . section "Special instructions"). When taking the drug simultaneously with gemfibrozil, fibrates, nicotinic acid in lipid-lowering doses, patients are recommended to take an initial dose of Rosucard® 5 mg; taking a dose of 40 mg is contraindicated when co-administered with fibrates (see sections “Contraindications”, “Dosage and Administration”, "Special instructions").
Fusidic acid:
There have been no specific drug interaction studies between fusidic acid and rosuvastatin, but isolated case reports of rhabdomyolysis have been noted.
Ezetimibe:
simultaneous use of Rosucard® at a dose of 10 mg and ezetimibe at a dose of 10 mg was accompanied by an increase in the AUC of rosuvastatin in patients with hypercholesterolemia (see Table 3). An increased risk of side effects due to the pharmacodynamic interaction between Rosucard® and ezetimibe cannot be excluded.
Antacids:
simultaneous use of rosuvastatin and antacid suspensions containing magnesium and aluminum hydroxide leads to a decrease in the plasma concentration of rosuvastatin by approximately 50%. This effect is less pronounced if antacids are used 2 hours after taking rosuvastatin. The clinical significance of this interaction has not been studied.
Erythromycin:
simultaneous use of rosuvastatin and erythromycin leads to a decrease in AUC of rosuvastatin by 20% and Cmax of rosuvastatin by 30%. This interaction may occur as a result of increased intestinal motility caused by erythromycin.
Isoenzymes of the cytochrome P450 system:
in vivo
and
in vitro
studies showed that rosuvastatin is neither an inhibitor nor an inducer of isoenzymes of the cytochrome P450 system. In addition, rosuvastatin is a weak substrate for these isoenzymes. Therefore, interaction of rosuvastatin with other drugs at the metabolic level involving isoenzymes of the cytochrome P450 system is not expected. There was no clinically significant interaction of rosuvastatin with fluconazole (an inhibitor of the CYP2C9 and CYP3A4 isoenzymes) and ketoconazole (an inhibitor of the CYP2A6 and CYP3A4 isoenzymes).
Interactions with drugs that require dose adjustment of rosuvastatin (see Table 3)
The dose of Rosucard® should be adjusted if it is necessary to use it together with drugs that increase the exposure of rosuvastatin. If an increase in exposure by 2 times or more is expected, the initial dose of Rosucard® should be 5 mg once daily. The maximum daily dose of Rosucard® should also be adjusted so that the expected exposure to rosuvastatin does not exceed that for a dose of 40 mg taken without the simultaneous administration of drugs that interact with rosuvastatin. For example, the maximum daily dose of Rosucard® when used simultaneously with gemfibrozil is 20 mg (increased exposure by 1.9 times), with ritonavir/atazanavir - 10 mg (increased exposure by 3.1 times).
Table 3. Effect of concomitant therapy on rosuvastatin exposure (AUC, data in descending order) - results from published clinical studies.
| Concomitant therapy regimen | Rosuvastatin dosage regimen | Change in rosuvastatin AUC |
| Cyclosporine 75-200 mg 2 times a day, 6 months. | 10 mg 1 time per day, 10 days | 7.1x magnification |
| Atazanavir 300 mg/ritonavir 100 mg once a day, 8 days | 10 mg, once | 3.1x magnification |
| Simeprevir 150 mg once a day, 7 days | 10 mg, once | 2.8x magnification |
| Lopinavir 400 mg/ritonavir 100 mg 2 times a day, 17 days | 20 mg 1 time per day, 7 days | 2.1x magnification |
| Clopidogrel 300 mg, then 75 mg over 24 hours | 20 mg, once | 2x magnification |
| Gemfibrozil 600 mg 2 times a day, 7 days | 80 mg, once | 1.9x magnification |
| Eltrombopag 75 mg once daily, 10 days | 10 mg, once | 1.6x magnification |
| Darunavir 600 mg/ritonavir 100 mg 2 times a day, 7 days | 10 mg 1 time per day, 7 days | 1.5 times magnification |
| Tipranavir 500 mg/ritonavir 200 mg 2 times a day, 11 days | 10 mg, once | 1.4x magnification |
| Dronedarone 400 mg 2 times a day. | No data | 1.4x magnification |
| Itraconazole 200 mg once a day, 5 days | 10 mg or 80 mg, once | 1.4x magnification |
| Ezetimibe 10 mg once a day, 14 days | 10 mg once a day, 14 days | 1.2 times magnification |
| Fosamprenavir 700 mg/ritonavir 100 mg 2 times a day, 8 days | 10 mg, once | Without changes |
| Aleglitazar 0.3 mg, 7 days | 40 mg, 7 days | Without changes |
| Silymarin 140 mg 3 times a day, 5 days | 10 mg, once | Without changes |
| Fenofibrate 67 mg 3 times a day, 7 days | 10 mg, 7 days | Without changes |
| Rifampin 450 mg once a day, 7 days | 20 mg, once | Without changes |
| Ketoconazole 200 mg 2 times a day, 7 days | 80 mg, once | Without changes |
| Fluconazole 200 mg once a day, 11 days | 80 mg, once | Without changes |
| Erythromycin 500 mg 4 times a day, 7 days | 80 mg, once | 28% reduction |
| Baikalin 50 mg 3 times a day, 14 days | 20 mg, once | 47% reduction |
The effect of rosuvastatin on other drugs.
Vitamin K antagonists:
Initiating therapy or increasing the dose of Rosucard® in patients receiving concomitant vitamin K antagonists (for example, warfarin) may lead to an increase in the International Normalized Ratio (INR). Discontinuation or reduction of the dose of Rosucard® may lead to a decrease in the INR. In such cases, INR monitoring is recommended.
Oral contraceptives/hormone replacement therapy:
simultaneous use of rosuvastatin and oral contraceptives increases the AUC of ethinyl estradiol and AUC of norgestrel by 26% and 34%, respectively. This increase in plasma concentration should be taken into account when selecting the dose of oral contraceptives. There are no pharmacokinetic data on the simultaneous use of Rosucard® and hormone replacement therapy; therefore, a similar effect cannot be excluded when using this combination. However, this combination was widely used during clinical trials and was well tolerated by patients.
Other medicines:
No clinically significant interaction between rosuvastatin and digoxin is expected.
ROSECARD
Interaction
The effect of the use of other drugs on rosuvastatin. Transport protein inhibitors:
rosuvastatin binds to some transport proteins, in particular OATP1B1 and BCRP. Concomitant use of drugs that are inhibitors of these transport proteins may be accompanied by an increase in the concentration of rosuvastatin in the blood plasma and an increased risk of developing myopathy (see Table 3 and sections “Dosage and Administration” and “Special Instructions”).
Cyclosporine:
with simultaneous use of rosuvastatin and cyclosporine, the AUC of rosuvastatin was on average 7 times higher than the value observed in healthy volunteers (see Table 3). Does not affect plasma concentrations of cyclosporine. ROZUKARD® is contraindicated in patients taking cyclosporine (see section "Contraindications").
Human immunodeficiency virus (HIV) protease inhibitors:
Although the exact mechanism of interaction is unknown, coadministration of HIV protease inhibitors may lead to a significant increase in rosuvastatin exposure (see Table 3). A pharmacokinetic study of co-administration of 20 mg rosuvastatin with a combination drug containing two HIV protease inhibitors (400 mg lopinavir/100 mg ritonavir) in healthy volunteers resulted in approximately two-fold and five-fold increases in AUC(0-24) and Cmax of rosuvastatin, respectively. Therefore, simultaneous use of ROZUKARD® and HIV protease inhibitors is not recommended (see sections “Dosage and Administration”, “Special Instructions”, Table 3).
Gemfibrozil and other lipid-lowering drugs:
The combined use of rosuvastatin and gemfibrozil leads to a 2-fold increase in the Cmax and AUC of rosuvastatin (see section “Special Instructions”). Based on specific interaction data, a pharmacokinetically significant interaction with fenofibrate is not expected; a pharmacodynamic interaction is possible. Gemfibrozil, fenofibrate, other fibrates and lipid-lowering doses of nicotinic acid (more than 1 g per day) increased the risk of myopathy when used concomitantly with HMG-CoA reductase inhibitors, possibly due to the fact that they can cause myopathy when used in monotherapy (see . section "Special instructions"). When taking the drug simultaneously with gemfibrozil, fibrates, nicotinic acid in lipid-lowering doses, patients are recommended to start with an initial dose of ROZUKARD® 5 mg; taking a dose of 40 mg is contraindicated when co-administered with fibrates (see sections “Contraindications”, “Dosage and Administration”, "Special instructions").
Fusidic acid:
There have been no specific studies on the drug interaction between fusidic acid and rosuvastatin, but there have been isolated reports of cases of rhabdomyolysis.
Ezetimibe:
simultaneous use of ROSUKARD® at a dose of 10 mg and ezetimibe at a dose of 10 mg was accompanied by an increase in the AUC of rosuvastatin in patients with hypercholestrinemia (see Table 3). An increased risk of side effects due to the pharmacodynamic interaction between ROZUKARD® and ezetimibe cannot be excluded.
Antacids:
simultaneous use of rosuvastatin and antacid suspensions containing magnesium and aluminum hydroxide. leads to a decrease in plasma concentrations of rosuvastatin by approximately 50%. This effect is less pronounced if antacids are used 2 hours after taking rosuvastatin. The clinical significance of this interaction has not been studied.
Erythromycin:
simultaneous use of rosuvastatin and erythromycin leads to a decrease in rosuvastatin AUC by 20% and rosuvastatin Cmax by 30%. This interaction may occur as a result of increased intestinal motility caused by erythromycin.
Isoenzymes of the cytochrome 1450 system:
in vivo
and
in vitro
studies showed that rosuvastatin is neither an inhibitor nor an inducer of isoenzymes of the cytochrome P450 system. In addition, rosuvastatin is a weak substrate for these isoenzymes. Therefore, interaction of rosuvastatin with other drugs at the metabolic level involving isoenzymes of the cytochrome P450 system is not expected. There was no clinically significant interaction of rosuvastatin with fluconazole (an inhibitor of the CYP2C9 and CYP3A4 isoenzymes) and ketoconazole (an inhibitor of the CYP2A6 and CYP3A4 isoenzymes).
Interactions with drugs that require dose adjustment of rosuvastatin (see Table 3)
The dose of ROSUKARD® should be adjusted if it is necessary to use it together with drugs that increase the exposure of rosuvastatin. If an increase in exposure by 2 times or more is expected, the initial dose of ROZUKARD® should be 5 mg once daily. The maximum daily dose of ROSUCARD® should also be adjusted so that the expected exposure to rosuvastatin does not exceed that for a dose of 40 mg taken without concomitant medications. interacting with rosuvastatin. For example, the maximum daily dose of ROZUKARD® when used simultaneously with gemfibrozil is 20 mg (increased exposure by 1.9 times), with ritonavir/atazanavir - 10 mg (increased exposure by 3.1 times).
Table 3. Effect of concomitant therapy on rosuvastatin exposure (AUC, data in descending order) - results from published clinical studies.
| Concomitant therapy regimen | Rosuvastat dosage regimen | Change in rosuvastatin AUC |
| Cyclosporine 75-200 mg 2 times a day.. 6 months. | 10 mg 1 time per day.. 10 days | 7.1x magnification |
| Atazanavir 300 mg/ritonavir 100 mg 1 time per day.. 8 days | 10 mg. once | 3.1x magnification |
| Simeprevir 150 mg once a day, 7 days | 10 mg, once | 2.8x magnification |
| Lopinavir 400 mg/ritonavir 100 mg 2 times a day, 17 days | 20 mg 1 time per day, 7 days | 2.1x magnification |
| Clopidogrel 300 mg. then 75 mg over 24 hours | 20 mg, once | 2x magnification |
| Gemfibrozil 600 mg 2 times a day, 7 days | 80 mg, once | 1.9x magnification |
| Eltrombopag 75 mg 1 time per day, 10 days | 10 mg, once | 1.6x magnification |
| Darunavir 600 mg/ritonavir 100 mg 2 times a day.. 7 days | 10 mg 1 time per day, 7 days | 1.5 times magnification |
| Tipranavir 500 mg/ritonavir 200 mg 2 times a day, 11 days | 10 mg. once | 1.4x magnification |
| Dronedarone 400 mg 2 times a day. | No data | 1.4x magnification |
| Itraconazole 200 mg 1 time per day, 5 days | 10 mg or 80 mg, once | 1.4x magnification |
| Ezetimibe 10 mg 1 time per day. 14 days | 10 mg once a day, 14 days | 1.2x magnification |
| Fosamprenavir 700 mg/ritonavir 100 mg 2 times a day, 8 days | 10 mg, once | bсз changes |
| Aleglitazar 0.3 mg, 7 days | 40 mg, 7 days | Without changes |
| Silymarin 140 mg 3 times a day, 5 days | 10 mg, once | Without changes |
| Fenofibrate 67 mg 3 times a day.. 7 days | 10 mg, 7 days | Without changes |
| Rifampin 450 mg once a day, 7 days | 20 mg, once | Without changes |
| Ketoconazole 200 mg 2 times a day, 7 days | 80 mg, once | Without changes |
| Fluconazole 200 mg 1 time per day, 11 days | 80 mg, once | Without changes |
| Erythromycin 500 mg 4 times a day, 7 days | 80 mg, once | 28% reduction |
| Baikalin 50 mg 3 times a day, 14 days | 20 mg, once | 47% reduction |
The effect of rosuvastatin on other drugs.
Vitamin K antagonists:
Initiating therapy or increasing the dose of ROSUCLRD® in patients receiving concomitant vitamin K antagonists (eg, warfarin) may lead to an increase in the International Normalized Ratio (INR). Discontinuation or reduction of the dose of ROZUKARD® may lead to a decrease in MHO. In such cases, M1IO control is recommended.
Oral contraceptives/hormone replacement therapy:
simultaneous use of rosuvastatin and oral contraceptives increases the AUC of ethinyl estradiol and AUC of norgestrel by 26% and 34%, respectively. This increase in plasma concentration should be taken into account when selecting the dose of oral contraceptives.
There are no pharmacokinetic data on the simultaneous use of ROZUKARD® and hormone replacement therapy; therefore, a similar effect cannot be excluded when using this combination. However, this combination was widely used during clinical trials and was well tolerated by patients.
Other medicines:
No clinically significant interaction between rosuvastatin and digoxin is expected.
Instructions for use of ROSUCARD®
Renal dysfunction
Proteinuria, detected using a test strip and mainly tubular in origin, was observed in patients receiving rosuvastatin in higher doses, namely 40 mg. Proteinuria is not a precursor to the development of acute or progressive renal failure. The incidence of serious renal impairment observed in post-marketing studies was higher at the 40 mg dose. Renal function should be assessed during routine examination of patients receiving the drug at a dose of 40 mg.
Musculoskeletal disorders
Musculoskeletal side effects such as myalgia, myopathy and, rarely, rhabdomyolysis have been observed in patients receiving rosuvastatin at any dose, particularly at doses greater than 20 mg. Rare cases of rhabdomyolysis have been observed in patients receiving ezetimibe in combination with HMG-CoA reductase inhibitors. A pharmacodynamic interaction between these drugs cannot be ruled out and caution should be exercised when using them together. As with other HMG-CoA reductase inhibitors, post-marketing reports of rhabdomyolysis with rosuvastatin were primarily associated with rosuvastatin 40 mg.
Control of creatine phosphokinase (CPK)
CPK levels should not be measured after heavy physical activity or if there is another reason for the increase in CPK levels, because this may lead to incorrect results. If the initial CPK level is significantly elevated (5 times the ULN), a repeat test should be performed within 5-7 days. If a repeat analysis confirms that the CPK level exceeds 5 times the normal level, treatment cannot be started.
Before treatment
The administration of rosuvastatin, like other HMG-CoA reductase inhibitors, is indicated with caution in patients with predisposing factors to the development of myopathy/rhabdomyolysis. These factors are:
- renal failure;
- hypothyroidism;
- patient or family history of muscle disorders;
- Providing a toxic effect on the muscles earlier when taking another HMG-CoA reductase inhibitor or fibrate;
- alcohol addiction;
- age over 70 years;
- situations in which an increase in plasma concentrations is possible;
- combined use with fibrates.
In such patients, the risk of therapy must be weighed against the expected effect, and inpatient monitoring is recommended. If the initial CPK level exceeds 5 times the normal CPK level, treatment cannot be started.
During treatment
Patients are advised to immediately report unexplained muscle pain, lethargy, or weakness, especially if accompanied by malaise or fever. CPK levels should be measured in these patients. Treatment should be discontinued if CPK levels exceed 5 times the normal CPK level or if muscle side effects are significant and cause daily discomfort (even if CPK levels exceed 5 times the normal CPK level). If symptoms resolve and CPK levels return to normal, rosuvastatin therapy may be resumed or another HMG-CoA reductase inhibitor at the lowest dose may be prescribed with careful monitoring of the patient. Routine monitoring of CPK levels in patients without these symptoms is not necessary.
In clinical trials, there was no evidence of an increase in musculoskeletal side effects in a small group of patients receiving rosuvastatin in combination with other drugs. However, an increase in the incidence of myositis and myopathy has been observed in patients receiving other HMG-CoA reductase inhibitors with fibrates, including gemfibrozil, cyclosporine, niacin, azole antifungals, protease inhibitors and macrolides. The use of gemfibrozil in combination with HMG-CoA reductase inhibitors increases the risk of developing myopathy. Therefore, concomitant use of rosuvastatin with gemfibrozil is not recommended. When using rosuvastatin together with fibrates or niacin, there are possible risks of side effects that should be taken into account when prescribing such combinations. The use of rosuvastatin at a dose of 40 mg is contraindicated when used together with fibrates. Rosuvastatin should not be administered to patients with acute conditions predisposing to the development of myopathy or with a predisposition to the development of renal failure due to rhabdomyolysis (eg, sepsis, hypotension, surgery, trauma, metabolic, endocrine and electrolyte disorders; or uncontrolled seizures).
Side effects on the liver
Like other HMG-CoA reductase inhibitors, rosuvastatin should be used with caution in patients who consume excessive amounts of alcohol or have a history of liver disease. It is recommended to conduct a liver function test before starting treatment and during the first 3 months. In cases where the content of transaminases exceeds ULN by 3 times, treatment is canceled. The potential for liver effects (primarily increased transaminase levels) is greater at the 40 mg dose.
In patients with secondary hypercholesterolemia caused by hypothyroidism or nephrotic syndrome, treatment begins with compensation of the underlying disease (before starting rosuvastatin therapy).
Race
Pharmacokinetic studies have shown that the drug has a stronger effect on representatives of the Mongoloid race than on representatives of the Caucasian race.
Protease inhibitors
Concomitant use with protease inhibitors is not recommended.
Chronic lung diseases with connective tissue damage
Interstitial lung disease has been reported in exceptional cases with the use of some statins, especially during long-term treatment. Difficulty breathing, a dry cough, and general deterioration in health (fatigue, weight loss, and fever) may also occur. If interstitial lung disease is suspected, statin therapy should be discontinued.
Diabetes
Some evidence suggests that statins may increase blood glucose levels and, in patients predisposed to diabetes mellitus, may lead to a level of hyperglycemia at which diabetes treatment may be appropriate. However, the benefits of statin treatment outweigh this risk, and therefore discontinuation of statin therapy is not required. Patients at risk (fasting glucose level - 5.6-6.9 mmol/l, BMI>30 kg/m2, elevated triglyceride levels, hypertension) should be under careful clinical and biochemical supervision in accordance with national requirements. In a clinical study, the overall incidence of diabetes mellitus reports was 2.8% in the rosuvastatin group and 2.3% in the placebo group, mainly in patients with fasting glucose levels between 5.6 and 6.9 mmol/L.
Children
Assessment of linear growth (height), body weight, BMI (body mass index) and secondary characteristics of puberty using the Tanner scale in children aged 10 to 17 years taking rosuvastatin is limited to a period of 1 year. After 52 weeks of the study, there was no effect of rosuvastatin treatment on height, weight, BMI or puberty. Clinical experience with the drug in children and adolescents is limited, and the long-term effect of rosuvastatin (more than 1 year) on puberty is unknown.
In clinical trials in children and adolescents taking rosuvastatin for 52 weeks, CPK levels were elevated (>10 times ULN) and muscle symptoms were more common post-exercise or following increased physical activity compared with observations in clinical trials in adults.
The drug contains lactose monohydrate, therefore the use of rosuvastatin is contraindicated in patients with hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome.
Impact on the ability to drive vehicles and operate machinery
Studies of the effect of rosuvastatin on the ability to drive a vehicle and control mechanical equipment have not been conducted. However, given the pharmacodynamic characteristics of the drug, caution should be exercised when driving vehicles or other mechanical vehicles (dizziness may occur during treatment with rosuvastatin).
